Bluebird Bio Stock Today
| BLUE Stock | USD 3.96 0.21 5.60% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Bluebird Bio is trading at 3.96 as of the 17th of March 2025, a 5.60 percent increase since the beginning of the trading day. The stock's lowest day price was 3.66. Bluebird Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of June 2013 | Category Healthcare | Classification Health Care |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. The company has 9.74 M outstanding shares of which 2.72 M shares are currently shorted by private and institutional investors with about 3.96 trading days to cover. More on Bluebird bio
Moving together with Bluebird Stock
Moving against Bluebird Stock
Bluebird Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Andrew Obenshain | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Blue Solutions SA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Health Care, Jakarta Stock Exchange, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBluebird Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bluebird Bio's financial leverage. It provides some insight into what part of Bluebird Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bluebird bio (BLUE) is traded on NASDAQ Exchange in USA. It is located in 455 Grand Union Boulevard, Somerville, MA, United States, 02145 and employs 282 people. Bluebird Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.53 M. Bluebird bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.74 M outstanding shares of which 2.72 M shares are currently shorted by private and institutional investors with about 3.96 trading days to cover.
Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Check Bluebird Bio Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Bluebird bio is $36.53 Million. 30% of Bluebird bio outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Bluebird Ownership Details
Bluebird Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-12-31 | 53.5 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 50.7 K | |
| Masters Capital Management Llc | 2024-12-31 | 48.8 K | |
| Fmr Inc | 2024-12-31 | 47.6 K | |
| Jane Street Group Llc | 2024-12-31 | 40.3 K | |
| Summit X, Llc | 2024-12-31 | 37.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 37.5 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 29.1 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 27.7 K | |
| Blackrock Inc | 2024-12-31 | 708.7 K | |
| Vanguard Group Inc | 2024-12-31 | 525.4 K |
Bluebird Bio Historical Income Statement
Bluebird Stock Against Markets
Bluebird Bio Corporate Management
| Mr MD | Chief Officer | Profile | |
| Melissa Bonner | VP Research | Profile | |
| Andrea Walton | Chief Officer | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Christopher CPA | Principal CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (36.00) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.